je.st
news
Tag: findings
Updated KEYTRUDA (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
2016-12-05 16:42:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma, who were ineligible for or failed to respond to autologous stem-cell transplantation (ASCT). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: of
large
updated
american
PAC 1 - Public Survey Findings
2016-11-17 22:02:41| PortlandOnline
November 2, 2016 PDF Document, 1,821kbCategory: South Waterfront Greenway - North Reach
Tags: public
survey
findings
pac
Findings from the Business Confidence Monitor Nigeria 2016/17 released
2016-11-16 11:00:00| BIFM News
Tags: business
monitor
released
confidence
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
2016-11-13 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the companys investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Presentation of New Findings for ZEPATIER (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting
2016-11-12 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting 2016, which provide additional evidence supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient populations, including those who receive opioid agonist therapy (OAT), are infected with chronic HCV GT1b, use proton pump inhibitors (PPIs) or have moderate kidney disease.
Tags: the
meeting
presentation
patients
Sites : [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] next »